You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

capecitabine

Showing 51 - 75 of 1,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Metastatic or Unresectable Solid Tumor Malignancy Trial in Fort Myers, Oklahoma City, Nashville (Capecitabine, Hsp90 Inhibitor

Completed
Has Results
  • Metastatic or Unresectable Solid Tumor Malignancy
  • Capecitabine
  • Hsp90 Inhibitor AUY 922
  • Fort Myers, Florida
  • +2 more
Feb 15, 2022

Biliary Tract Tumor Trial in Nanjing (Tislelizumab, Lenvatinib, Oxaliplatin)

Recruiting
  • Biliary Tract Tumor
  • Nanjing, Jiangsu, China
    Jiangsu Province Hospital
Mar 14, 2022

Colorectal Tumors Trial in Philadelphia (bevacizumab, cetuximab, Oxaliplatin)

Terminated
Has Results
  • Colorectal Neoplasms
  • Philadelphia, Pennsylvania
    Fox Chase Cancer Center
Dec 30, 2021

Colorectal Tumors Trial in Heidelberg (Capecitabine, 131I-huA33 (131-Iodine on humanised mAb A33))

Completed
Has Results
  • Colorectal Neoplasms
  • Capecitabine
  • 131I-huA33 (131-Iodine on humanised monoclonal antibody A33)
  • Heidelberg, Victoria, Australia
    Ludwig Institute Oncology Unit and Tumor Targeting Program, Aust
Jan 11, 2022

Triple Negative Breast Cancer, Breast Cancer Trial in Stanford (Capecitabine)

Recruiting
  • Triple Negative Breast Cancer
  • Breast Cancer
  • Capecitabine
  • Stanford, California
    Stanford University
Jan 7, 2022

Colorectal Cancer Metastatic Trial in Milano, Pisa (Capecitabine, Bevacizumab, Trifluridine/Tipiracil)

Recruiting
  • Colorectal Cancer Metastatic
  • Capecitabine
  • +2 more
  • Milano, MI, Italy
  • +1 more
Feb 2, 2022

Metastatic Triple-Negative Breast Cancer Trial in Beijing (Anlotinib, Capecitabine)

Recruiting
  • Metastatic Triple-Negative Breast Cancer
  • Beijing, Beijing, China
  • +1 more
Dec 18, 2021

Esophageal Squamous Cell Carcinoma Trial in Beijing (nab-paclitaxel, Cisplatin, Capecitabine)

Recruiting
  • Esophageal Squamous Cell Carcinoma
  • Beijing, China
    National Cancer Center/Cancer Hospital, Chinese Academy of Medic
Mar 13, 2022

Nasopharyngeal Carcinoma Trial in Guangzhou (PD-1 antibody, Capecitabine)

Recruiting
  • Nasopharyngeal Carcinoma
  • PD-1 antibody
  • Capecitabine
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Apr 17, 2022

Colorectal Tumors, Stomach Tumor, Esophageal Tumors Trial in Cork, Dublin 8 (Lithium, Oxaliplatin, Capecitabine)

Recruiting
  • Colorectal Neoplasms
  • +2 more
  • Cork, Ireland
  • +1 more
Feb 9, 2022

Gastric Cancer, GastroEsophageal Cancer Trial in China (SHR-1210, Capecitabine, Oxaliplatin)

Completed
  • Gastric Cancer
  • GastroEsophageal Cancer
  • SHR-1210
  • +3 more
  • Hefei, Anhui, China
  • +9 more
Jun 30, 2022

Advanced Malignant Solid Tumor, Bile Duct Carcinoma, Recurrent Malignant Solid Tumor Trial in Indianapolis, Seattle (Afatinib

Completed
  • Advanced Malignant Solid Neoplasm
  • +6 more
  • Afatinib Dimaleate
  • +2 more
  • Indianapolis, Indiana
  • +1 more
Jun 3, 2022

Invasive Mammary Carcinoma, Metastatic Breast Cancer Trial in Nashville (Capecitabine, Endocrine-therapy, MammoPrint ® and

Not yet recruiting
  • Invasive Mammary Carcinoma
  • Metastatic Breast Cancer
  • Capecitabine
  • +2 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
Jan 11, 2023

Head and Neck Squamous Cell Carcinoma Trial in Guangzhou (Capecitabine)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Capecitabine
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 15, 2022

Brain Metastases, Breast Cancer, Metastatic Breast Cancer Trial in Multiple Locations (BKM120, capecitabine, Trastuzumab)

Completed
Has Results
  • Brain Metastases
  • +2 more
  • Multiple Locations, Texas
    Please contact Zuzanne Bristow for list of sites
Jan 31, 2022

Gastric Cancer Trial in Gyeonggi-do (Oxaliplatin, Capecitabine)

Recruiting
  • Gastric Cancer
  • Gyeonggi-do, Korea, Republic of
    Hallym University Medical Center
Feb 4, 2022

Biliary Tract Cancer Trial in Shanghai (ZKAB001 5mg/kg, Capecitabine)

Enrolling by invitation
  • Biliary Tract Cancer
  • ZKAB001 5mg/kg
  • Capecitabine
  • Shanghai, China
    Renji Hospital Affiliated to School of Medicine, Shanghai Jiaoto
Jan 10, 2022

Epstein-Barr Virus Positive, Gastric Adenocarcinoma, Mismatch Repair Protein Deficiency Trial in New Brunswick (drug, other,

Recruiting
  • Epstein-Barr Virus Positive
  • +10 more
  • Capecitabine
  • +3 more
  • Atlanta, Georgia
  • +2 more
Dec 10, 2022

Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma, Pancreatic Adenocarcinoma Trial in

Completed
  • Borderline Resectable Pancreatic Adenocarcinoma
  • +6 more
  • Capecitabine
  • +4 more
  • Houston, Texas
  • +4 more
Aug 31, 2022

Colorectal Cancer, Colon Cancer, Rectal Cancer Trial in Cleveland (CB-839, Capecitabine)

Active, not recruiting
  • Colorectal Cancer
  • +3 more
  • Cleveland, Ohio
  • +1 more
Jan 14, 2022

Breast Cancer Trial in United States (Capecitabine, Neratinib, EORTC QLQ - BR23, EQ-5D-5L, EORTC QLQ-C30)

Active, not recruiting
  • Breast Cancer
  • Capecitabine
  • +2 more
  • Hartford, Connecticut
  • +9 more
Apr 15, 2022

Metastatic Pancreatic Cancer Trial in Baltimore (Nab-paclitaxel, Gemcitabine, Cisplatin)

Recruiting
  • Metastatic Pancreatic Cancer
  • Baltimore, Maryland
    Sidney Kimmel Comprehensive Cancer Center
Mar 14, 2022

Breast Cancer, Triple Negative Breast Tumors Trial in France (Nivolumab, Ipilimumab, Capecitabine)

Active, not recruiting
  • Breast Cancer
  • Triple Negative Breast Neoplasms
  • Angers, France
  • +16 more
Jul 21, 2022

Colorectal Cancer, Lung Cancer, Solid Tumor Trial in Ottawa, Toronto (capecitabine, carboplatin, cediranib maleate)

Completed
  • Colorectal Cancer
  • +2 more
  • capecitabine
  • +3 more
  • Ottawa, Ontario, Canada
  • +1 more
Mar 14, 2022

Early Low Rectal Cancer Trial in Shanghai (PD-1 antibody, Capecitabine, Oxaliplatin)

Recruiting
  • Early Low Rectal Cancer
  • PD-1 antibody
  • +3 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Jan 9, 2023